Novavax, Inc. reports net loss for Q2, beats by penny
Biopharmaceutical company Novavax, Inc. (Nasdaq: NVAX) reported a net loss for the second-quarter, beating estimates by a penny.
For the three months ended June 30, the Rockville, Md.-based company reported a net loss of $8.2 million, or $0.13 loss per share, while three analysts polled by Thomson Financial were expecting a loss of $0.14 per share. This compares with a net loss of $6.4 million, $0.10 loss per share, in the second quarter of 2006.
Revenues for the second quarter were $0.2 million, falling short of the consensus of three analysts polled by Thomson Financial of $0.9 million. Revenues for the same period last year were $0.8 million.
The company also informed investors of major expected announcements for the second half of the year, including the announcement of two new vaccine candidates in late-stage discovery, pre-clinical results for its seasonal flu VLP vaccine candidates and interim results from the company’s Phase I/IIa pandemic flu vaccine trial.
Novavax was halted in pre-market trading.
